Rampart One Lumbar Interbody Fusion Device

K180002 · Spineology, Inc. · OVD · Apr 25, 2018 · Orthopedic

Device Facts

• Record ID: K180002
• Device Name: Rampart One Lumbar Interbody Fusion Device
• Applicant: Spineology, Inc.
• Product Code: OVD · Orthopedic
• Decision Date: Apr 25, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The standard and oblique Rampart One devices are integrated intervertebral body fusion devices indicated for intervertebral body fusion at one level or two contiguous levels in the lumbar spine from L2 to S1 in patients with degenerative disc disease (DDD) with up to Grade I spondylolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies. These patients should be skeletally mature and had six months non-operative treatment. The standard and oblique Rampart One devices are designed for use with autograft and/or allograft comprised of cancellous bone graft. The standard Rampart One device may be used with or without supplemental fixation systems cleared by FDA for use in the lumbar spine. When used without supplemental fixation, the standard Rampart One device must be used with four (4) screws. The oblique Rampart One device must be used with supplemental fixation systems cleared by FDA for use in the lumbar spine.

Device Story

Intervertebral body fusion device; stabilizes spinal segments as adjunct to fusion. Device consists of PEEK-OPTIMA HA Enhanced spacer, titanium alloy face plate, and tantalum radiopaque markers. Integrated fixation via titanium alloy screws inserted through anterior face plate into adjacent vertebral bodies. Standard configuration (4 screws) or oblique configuration (2 screws). Used in lumbar spine (L2-S1). Implanted by surgeon during fusion procedure; hollow core packed with autograft/allograft bone graft. Standard device may be used as stand-alone (without supplemental fixation) or with supplemental fixation; oblique device requires supplemental fixation. Provides mechanical stability to disc space to facilitate fusion; benefits patient by reducing pain associated with discogenic degeneration.

Clinical Evidence

No new clinical testing performed. Evidence consists of a review of published clinical data for stand-alone anterior lumbar intervertebral body fusion devices with integrated fixation, demonstrating no new risks.

Technological Characteristics

Materials: PEEK-OPTIMA HA Enhanced (spacer), titanium alloy (face plate), tantalum (markers). Integrated fixation via titanium alloy screws. Testing standards: ASTM F2077 (static/dynamic compression, subsidence), ASTM F2267 (axial pullout), ASTM F543-13 (static/dynamic compression shear, anti-screw backout, expulsion). Sterilization: Not specified.

Indications for Use

Indicated for skeletally mature patients with degenerative disc disease (DDD) and up to Grade I spondylolisthesis at one or two contiguous lumbar levels (L2-S1) who have failed six months of non-operative treatment.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• Rampart™ One Lumbar Interbody Fusion Device (K163670)
• SYNFIX™ Evolution Secured Spacer System (K150673)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters 'FDA' in a blue square, followed by the words 'U.S. FOOD & DRUG ADMINISTRATION' in blue text.

April 25, 2018

Spineology Inc. Jacqueline Hauge Regulatory Affairs Manager 7800 3rd Street N.. Suite 600 St. Paul, Minnesota 55128

Re: K180002

Trade/Device Name: Rampart™ One Lumbar Interbody Fusion Device Regulation Number: 21 CFR 888,3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: OVD Dated: March 23, 2018 Received: March 26, 2018

Dear Ms. Hauge:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

# Vincent J. Devlin -S

for

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known) K180002

Device Name

Rampart™ One Lumbar Interbody Fusion Device

### Indications for Use (Describe)

The standard and oblique Rampart One devices are integrated intervertebral body fusion devices indicated for intervertebral body fusion at one level or two contiguous levels in the lumbar spine from L2 to S1 in patients with degenerative disc disease (DDD) with up to Grade I spondylolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies. These patients should be skeletally mature and had six months non-operative treatment. The standard and oblique Rampart One devices are designed for use with autograft and/or allograft comprised of cancellous bone graft.

The standard Rampart One device may be used with or without supplemental fixation systems cleared by FDA for use in the lumbar spine. When used without supplemental fixation, the standard Rampart One device must be used with four (4) screws.

The oblique Rampart One device must be used with supplemental fixation systems cleared by FDA for use in the lumbar spine.

| Type of Use (Select one or both, as applicable) |
|-------------------------------------------------|
|-------------------------------------------------|

| Prescription Use (Part 21 CFR 801 Subpart D) | <div></div> |
|----------------------------------------------|-------------|
| Over-The-Counter Use (21 CFR 801 Subpart C) | <div></div> |

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for Spineology. The word "Spineology" is written in a bold, sans-serif font, with the letters in black. To the right of the word is a graphic of a cluster of purple dots arranged in a circular pattern. The logo is simple and modern, and the use of color is eye-catching.

## 510(k) Summary

Inc.)

| Date Prepared: | April 19, 2018 |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Submitter: | Spineology Inc.<br>7800 3rd Street North<br>Suite 600<br>Saint Paul, MN 55128<br>Establishment Registration Number: 2135156 |
| Contact Person: | Jacqueline A. Hauge<br>Regulatory Affairs Manager<br>Phone: [phone]<br>Fax: [phone]<br>Email: [e-mail] |
| Device Name and Classification | |
| Trade Name: | Rampart™ One Lumbar Interbody Fusion Device |
| Common Name: | Intervertebral fusion device with integrated fixation |
| Classification Name: | OVD |
| Regulatory Class: | Class II |
| Regulation Number: | 21 CFR 888.3080 |
| Panel: | Orthopedic |
| Predicate Devices | |
| Primary: | K163670 Rampart™ One Lumbar Interbody Fusion Device (Spineology |
| Additional: | K150673 SYNFIX™ Evolution Secured Spacer System (Synthes Spine) |

#### Purpose of Submission A.

The purpose of this submission is to expand the indications for use statement to allow the option to use the standard Rampart One implantable device as a stand-alone Anterior Lumbar Interbody Fusion (ALIF) device (without supplemental fixation systems cleared by FDA for use in the lumbar spine).

#### B. Device Description

Rampart One implants are intervertebral body fusion devices for use with bone graft in the intervertebral disc space to stabilize spinal segments as an adjunct to fusion. These devices are manufactured from PEEK-OPTIMA HA Enhanced (spacer), titanium alloy (face plate), and tantalum (radiopaque markers) materials. Rampart One devices incorporate integrated fixation in the form of titanium alloy screws. Rampart One devices are provided in standard and oblique configurations. The standard device accommodates four screws and the oblique device accommodates two screws. In each device, the screws are inserted through the anteriorly-located face plate into the adjacent vertebral bodies. Rampart One devices are provided in various heights and lordotic angles and contain a hollow core to receive autograft and/or allograft comprised of cancellous and/or corticocancellous bone graft. Placement is achieved with an insertion instrument that allows for manipulation of the implant in the intervertebral disc space.

{4}------------------------------------------------

#### C. Indications for Use

The standard and oblique Rampart One devices are integrated intervertebral body fusion devices indicated for intervertebral body fusion at one level or two contiguous levels in the lumbar spine from L2 to S1 in patients with degenerative disc disease (DDD) with up to Grade I spondylolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies. These patients should be skeletally mature and have had six months non-operative treatment. The standard and oblique Rampart One devices are designed for use with autograft and/or allograft comprised of cancellous and/or corticocancellous bone graft.

The standard Rampart One device may be used with or without supplemental fixation using fixation systems cleared by FDA for use in the lumbar spine. When used without supplemental fixation, the standard Rampart One device must be used with four (4) screws.

The oblique Rampart One device must be used with two (2) screws and with supplemental fixation systems cleared by FDA for use in the lumbar spine.

#### D. Comparison to Predicate Device

There have been no design changes to the standard and oblique Rampart One devices since there last clearance; therefore, when compared to the predicate device, the Rampart One Lumbar Interbody Fusion Device has the same:

- Intended Use
- Indications for Use
- Fundamental Scientific Technology
- Principle of Operation
- Materials ●
- Biocompatibility
- Size Offering

#### E. Non-Clinical Testing

New performance testing was not performed or required to support the modifications for use statement. The initial performance testing conducted for the Rampart One device remains valid and the data obtained provides reasonable assurance of the safety and effectiveness of the Rampart One device when used within the context and limitations of the intended use.

The previously conducted performance testing established conformance to the following:

ASTM F2077

ASTM 2267

ASTM F543-13

- Static and Dynamic Compression ●
• Subsidence

. Axial Pullout

- Static and Dynamic Compression Shear ●
Anti-Screw Backout

Expulsion Bacterial Endotoxin Testing (BET) conducted in accordance with ANSI/AAMI FT-72:2011

#### F. Clinical Testing

A review of published clinical data for stand-alone anterior lumbar intervertebral body fusion devices with integrated fixation was provided in support of this application. The published clinical outcomes demonstrate that the use of such devices to treat patients with disc disease, as defined above, poses no new risks to patients. No new components were added to the Rampart One system, nor were any substantive design changes made to the existing devices; therefore, clinical testing was not required or performed to support substantial equivalence.

{5}------------------------------------------------

#### G. Conclusion

Based on the indications for use, technological characteristics, comparison to the predicate devices, and supportive literature review, Spineology has demonstrated that the Rampart One Lumbar Interbody Fusion Device is substantially equivalent to the legally marketed predicate device.